Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Aurora Cannabis Inc.NASDAQ: ACB

Net Income · Q4 FY2026 · quarter ended Mar 2026

Net income turns positive

Q4 FY2026 net income was CA$15.71M, compared with -CA$21.98M a year earlier. Trailing-twelve-month net income was -CA$58.58M. Over 3 fiscal years it compounded at -39.5% a year.

Context

  • Net income amounted to 18.3% of revenue in FY2026, up 13.7 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -CA$26.79M (-54.4%) for the fiscal year ending Mar 2027, a step up from the -472.8% reported in FY2026.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$15.71M+1001.3% QoQ
Last fiscal yearMar 2026
-CA$58.77M-472.8% YoY
LTMMar 2026
-CA$58.58M-507.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+171.5%-37.4%-208.9 pp
1 year-472.8%-54.4%+418.4 pp
3-year CAGR-39.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CAD · from the cash flow

Latest · FY2026
(58.77M) CAD
Year-over-year change
-472.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -507.7% is the lowest of 10, against a peer median of -26.3%.
  • Net income amounts to 18.8% of revenue for ACB, versus a peer median of 43.5%.
ACB Competitors
Net Income for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$286.21M CAD-52.6%-50.8%91.6%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$165.86M USD+628.0%-48.4%45.9%
EDITEditas Medicine, Inc.LTM Mar 2026$108.95M USD-56.6%-10.1%281.6%
BIOABioAge Labs, Inc.LTM Mar 2026$89.93M USD+26.6%+26.6%871.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M USD-46.5%-9.3%832.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$58.58M CAD-507.7%-39.5%18.8%
HITIHigh Tide Inc.LTM Apr 2026CA$46.43M CAD+388.6%-10.1%6.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$34.09M USD—-30.8%25.2%
OGIOrganigram Global Inc.LTM Mar 2026CA$25.23M CAD-249.4%—9.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$17.17M USD-26.3%-28.6%41.1%
LFMDLifeMD, Inc.LTM Mar 2026$507.37K USD+105.0%—0.2%
Peer median (excluding ACB) —-26.3%-19.4%43.5%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Net Income(1.72B)(265.33M)(57.08M)15.76M(58.77M)
Depreciation & Amortization93.66M43.57M32.78M22.55M14.23M
Deferred Income Tax(2.19M)(18.4M)(1.67M)(3.19M)55.14K
Stock-Based Compensation13.76M16.89M12.72M11.52M7.29M
Change in Working Capital52.65M(25.12M)(15.54M)10.21M(9.24M)
Accounts Receivables18.34M5.53M(4.5M)5.24M(8.17M)
Inventory21.07M49.03M3.87M(15.05M)65.93M
Accounts Payables6.77M(8.06M)(15.7M)14.91M(8.06M)
Other Working Capital6.48M(71.61M)790K5.11M(58.93M)
Other Non-Cash Items1.45B190.11M(39.71M)(40.85M)40.18M
Operating Cash Flow(110.27M)(115.82M)(68.51M)16.01M(13.55M)
Capital Expenditures(32.21M)(12.13M)(16.83M)(18.86M)(22.6M)
Acquisitions (Net)(23.42M)(18.54M)(5.55M)01.1M
Purchases of Investments0000(52.35M)
Sales of Investments03.36M4.99M5.49M0
Other Investing Activities19.46M16K14.02M(956K)235.61K
Investing Cash Flow(36.17M)(27.29M)(3.36M)(14.33M)(73.62M)
Debt Repayment(170.83M)—(85.37M)(805K)(5.02M)
Common Stock Issued350.19M73.19M37.92M820K9.94M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(31.58M)(95.21M)(475K)(131K)(154.4K)
Financing Cash Flow147.78M(56.48M)(47.92M)(116K)9.79M
Effect of Forex Changes15.01M15.54M297K264K10.56M
Net Change in Cash16.35M(140.01M)(119.5M)1.83M(66.81M)
Free Cash Flow(142.48M)(127.95M)(85.34M)(2.85M)(36.15M)

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.